Literature DB >> 28333340

Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.

Faiza Mougari, Jade Loiseau, Nicolas Veziris1,2,3, Christine Bernard1,2,3, Béatrice Bercot, Wladimir Sougakoff1,2,3, Vincent Jarlier1,2,3, Laurent Raskine1,4, Emmanuelle Cambau.   

Abstract

Objectives: Non-tuberculous mycobacteria (NTM) are emerging pathogens causing difficult-to-treat infections. We tested a new assay (GenoType NTM-DR) that detects natural and acquired resistance mechanisms to macrolides and aminoglycosides in frequently isolated NTM species.
Methods: Performance was assessed on 102 isolates including reference strains [16 Mycobacterium avium , 10 Mycobacterium intracellulare , 8 Mycobacterium chimaera , 15 Mycobacterium chelonae and 53 Mycobacterium abscessus (including subsp. abscessus isolates, 18 with a t28 in erm(41) and 10 with a c28, 13 subsp. bolletii isolates and 12 subsp. massiliense isolates)]. Genotypes were determined by PCR sequencing of erm(41) and rrl for clarithromycin resistance and of the 1400-1480 rrs region for aminoglycoside resistance. Phenotypes were determined by MIC microdilution.
Results: GenoType NTM-DR yielded results concordant with Sanger sequencing for 100/102 (98%) isolates. The erm(41) genotypic pattern was accurately identified for M. abscessus isolates . Mutations in rrl were detected in 15 isolates (7 M. avium complex, 5 M. abscessus and 3 M. chelonae ) with acquired clarithromycin resistance harbouring rrl mutations (a2057c, a2058g, a2058t or a2059c). Mutations in rrs were detected in five isolates with amikacin resistance harbouring the rrs mutation a1408g. In two isolates, the NTM-DR test revealed an rrl mutation (initial sequencing being WT), which was confirmed by re-sequencing. The test results were concordant with phenotypic susceptibility testing in 96/102 (94.1%) isolates, with four clarithromycin-resistant and two amikacin-resistant isolates not harbouring mutations. Conclusions: The GenoType NTM-DR test is efficient in detecting mutations predictive of antimicrobial resistance in M. avium complex, M. abscessus and M. chelonae.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28333340     DOI: 10.1093/jac/dkx021

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates.

Authors:  Simone Mok; Margaret M Hannan; Lars Nölke; Patrick Stapleton; Niamh O'Sullivan; Philip Murphy; Anne Marie McLaughlin; Eleanor McNamara; Margaret M Fitzgibbon; Thomas R Rogers
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Identification of Mycobacterium abscessus species and subspecies using the Cas12a/sgRNA-based nucleic acid detection platform.

Authors:  Guohui Xiao; Su Zhang; Zhihang Liang; Guanqiang Li; Mutong Fang; Yaya Liu; Juanjuan Zhang; Min Ou; Xing He; Tianyu Zhang; Changchun Zeng; Lei Liu; Guoliang Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-28       Impact factor: 3.267

Review 3.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

4.  GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.

Authors:  Hee Jae Huh; Su-Young Kim; Hyang Jin Shim; Dae Hun Kim; In Young Yoo; On-Kyun Kang; Chang-Seok Ki; So Youn Shin; Byung Woo Jhun; Sung Jae Shin; Charles L Daley; Won-Jung Koh; Nam Yong Lee
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

5.  Mycobacterium ChelonaeDeveloping Multidrug Resistance.

Authors:  Vinod Kumar Mannelli; Manoj P Rai; Divyesh Reddy Nemakayala; Naga Preethi Kadiri
Journal:  BMJ Case Rep       Date:  2018-02-22

6.  A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish Mycobacterium abscessus Subspecies and Determine Macrolide Susceptibility.

Authors:  Salvatore A E Marras; Liang Chen; Elena Shashkina; Rebecca M Davidson; Michael Strong; Charles L Daley; Barry N Kreiswirth
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

Review 7.  Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.

Authors:  Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin
Journal:  Clin Pharmacokinet       Date:  2021-03-10       Impact factor: 6.447

Review 8.  Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Authors:  Kai Ling Chin; Maria E Sarmiento; Nadine Alvarez-Cabrera; Mohd Nor Norazmi; Armando Acosta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

9.  Species identification and antimicrobial susceptibility testing of non-tuberculous mycobacteria isolated in Chongqing, Southwest China.

Authors:  Huizheng Zhang; Ming Luo; Ke Zhang; Xin Yang; Kui Hu; Zongqiang Fu; Liwen Zhang; Ping Wu; Dongyong Wan; Mei Han; Xiaoying Wang
Journal:  Epidemiol Infect       Date:  2020-12-28       Impact factor: 2.451

10.  Drug susceptibility profiles and factors associated with non-tuberculous mycobacteria species circulating among patients diagnosed with pulmonary tuberculosis in Tanzania.

Authors:  Togolani Godfrey Maya; Erick Vitus Komba; Gloria Ivy Mensah; Peter Masunga Mbelele; Stella George Mpagama; Sayoki Godfrey Mfinanga; Kennedy Kwasi Addo; Rudovick Reuben Kazwala
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.